NEW YORK, Nov. 29 (GenomeWeb News) - SeraCare Life Sciences will acquire Serologicals' Celliance subsidiary for $3.7 million in cash and "certain liabilities," the companies said today
SeraCare, based in Oceanside, Calif., will buy Celliance's Milford, Mass.-based diagnostic manufacturing facilities and its product lines.
Celliance, which in October acquired gene-expression technology from Innovata, primarily offers products for cell culture and diagnostic applications. The acquisition is aimed at increasing SeraCare's footprint in molecular diagnostic reagents, diagnostic intermediates, and substrates, President and CEO Michael Crowley said in a statement.
The acquisition is expected to close in January, SeraCare said. Further details were not disclosed.
SeraCare has facilities in Cambridgeand Bridgewater, Mass.; Frederickand Gaithersburg, Md.; and Hatboro, Penn.It sells plasma-based therapeutic products, diagnostic products, and reagents; cell culture products; specialty plasmas; in vitro stabilizers; and a clinical sample repository for use in drug discovery and development.